Efficacy of fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer: a preliminary report (Q35142182)

6 August 2017

Efficacy of fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer: a preliminary report (English)

1 reference

6 August 2017

Changhoon Yoo

1

1 reference

6 August 2017

Sung-Bae Kim

2

1 reference

6 August 2017

Jin-Hee Ahn

3

1 reference

6 August 2017

Kyung Hae Jung

4

1 reference

6 August 2017

Yongchel Ahn

5

1 reference

6 August 2017

Gyungyub Gong

6

1 reference

6 August 2017

Hak-Hee Kim

7

1 reference

6 August 2017

Hee-Jung Kim

8

1 reference

6 August 2017

Byung-Ho Son

9

1 reference

6 August 2017

Sei-Hyun Ahn

10

1 reference

6 August 2017

18 June 2011

1 reference

6 August 2017

Journal of breast cancer

1 reference

6 August 2017

14

1 reference

6 August 2017

2

1 reference

6 August 2017

135-139

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

6 August 2017

start time

1 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Fulvestrant (Faslodex) -- how to make a good drug better

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3148533

Early- and late-onset breast cancer types among women in the United States and Japan

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3148533

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3148533

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3148533

A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3148533

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3148533

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3148533

Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3148533

Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3148533

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3148533

Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3148533

Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3148533

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3148533

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3148533

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3148533

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3148533

Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21847409

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4048/JBC.2011.14.2.135

1 reference

6 August 2017

1 reference

6 August 2017

1 reference